Zelira TherapeuticsZLDAF 10 EBITDA Margin % is 0.00% as of Jun. 2025. GuruFocus rates ZLDAF with a GF Score™ of 10/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 942 Biotechnology companies, Zelira Therapeutics ranks worse than 99.04% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zelira Therapeutics EBITDA Margin % Related Terms
Zelira Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zelira Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZLDAF vs MTNB, SXTP, GLMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Zelira Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zelira Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zelira Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zelira Therapeutics (ZLDAF) has a EBITDA Margin % of 0.00% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zelira Therapeutics and its competitors. According to the industry distribution chart, Zelira Therapeutics ranks #933 out of 942 companies in the Biotechnology industry, placing it in the top 99%.
Is Zelira Therapeutics' EBITDA Margin % too high?
Zelira Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Zelira Therapeutics ranks #933 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zelira Therapeutics has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zelira Therapeutics' EBITDA Margin % compare to MTNB and SXTP?
According to the Biotechnology industry distribution chart, Zelira Therapeutics ranks #933 out of 942 companies for EBITDA Margin %. This places Zelira Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zelira Therapeutics (ZLDAF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.35 — trading 337.5% above its estimated fair value. The current EBITDA Margin % is 0.00%. Zelira Therapeutics' overall GF Score™ is 10/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zelira Therapeutics (ZLDAF), the current EBITDA Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zelira Therapeutics (ZLDAF) Overvalued in 2026?
Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued.
The current stock price of $0.35 is trading 337.5% above its estimated GF Value™ of $0.08.
GuruFocus considers Zelira Therapeutics to be Significantly Overvalued.
Key valuation signals for ZLDAF:
EBITDA Margin %: 0.00%
GF Value™: $0.08 vs. price of $0.35 (337.5% above fair value)
No single metric tells the full story. See the ZLDAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
10GF Score
Get the complete analysis for ZLDAF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDAF has been successfully added to your 
